The earnings result
ResMed| reported earnings on 2024-01-24 for the fiscal quarter ending Dec/2023. Reported EPS of $1.88 compared with a consensus estimate of $1.81, a beat on the source's earnings measure.
An EPS comparison describes one part of the release. Revenue, segment performance, cash conversion, guidance and the conference-call discussion require the original company disclosures; the result alone does not establish why the stock moved.
The market response
Price baseline: report-date close; announcement time unavailable. The source does not identify whether this report was before or after trading. These are subsequent daily returns, not a verified immediate earnings reaction.
The first measured session returned +8.48% from the stated baseline. The five-session return was +10.72%, and the 20-session return was +6.59%. SPY returned +4.56% across the corresponding window. Relative volume was 3.21 times the preceding 20-session average.
This edition is a source-based earnings-result and market-response analysis. A full financial-statement and conference-call dossier is not yet attached.